Assessment: Symptomatic Treatment for Muscle Cramps (an Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:691-696, Katzberg,H.D.,et al, 2010
What All Physicians Need to Know About the Polio Resurgence in New York State
JAMA online e1-e3, Larkin, H., 2022
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Practice Guideline: Idiopathic Normal Pressure Hydrocephalus: Response to Shunting and Predictors of Response
Neurol 85:2063-2071, Halperin, J.J.,et al, 2015
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Misdiagnosis of Treatable Stroke Mimic: The Case for HIV Screening in Practice Guidelines
Neurohosp 3:125-130, Finelli, P.F., 2013
Evidence-based Guideline: Diagnostic accuracy of CSF 14-3-3 Protein in Sporadic Creutzfeldt-Jakob Disease
Neurol 79:1499-1506, Muayqil, T.,et al, 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Predictors of Neurologic Outcome in Hypothermia After Cardiac Arrest
Ann Neurol 68:907-914, Fugate,J.E.,et al, 2010
Practice Parameter Update: The Care of the Patient with Amyotrophic Lateral Sclerosis: Drug, Nutritional, and Respiratory Therapies (An Evidence-Based Review)
Neurol 73:1218-1226, Miller,R.G.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Practice Parameter: Assessing Patients in a Neurology Practice for Risk of Falls (An Evidence-Based Review)
Neurol 70:473-479, Thurman,D.J.,et al, 2008
Second Consensus Statement on the Diagnosis of Multiple System Atrophy
Neurol 71:670-676, Gilman,S.,et al., 2008
Practice Parameter: Corticosteroid Treatment of Duchenne Dystrophy
Neurol 64:13-20, Moxley,R.T. III.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis
Neurol 61:1332-1338, Goodin,D.S.,et al, 2003
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
Clinical Utility of Surface EMG: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 55:171-177, Pullman,S.L. et al, 2000
Practice Parameter:The Care of the Patient with Amyotrophic Lateral Sclerosis (An Evidence-Based Review), Report of the Quality Standards Subcommittee of the AAN
Neurol 52:1311-1323, Miller,R.G.,et al, 1999
ALS Standard of Care Consensus
Neurol 48 (Suppl 4) :S33-S37997., Miller,R.G.,et al, 1997
Practice Advisory on the Trtm of ALS with Riluzole
Quality Standards Subcommittee of the AAN, Neurol 49:657-6591997., , 1997